Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis

Inclusion Criteria:

1. Aged ≥ 20 years and ≤ 75 years at screening.

2. Patients with written informed consent form.

3. Male or female diagnosed with SLE.

4. Confirmed diagnosis of LN by physician. Diagnosis of LN is defined as:

a. Kidney biopsy within 1 year, with histological diagnosis of LN (class III/IV/V)

5. Laboratory evidence of active nephritis: spot UPCR>0.5, and/or proteinuria > 0.5
g/24 hours, and/or greater than 3+ by dipstick, and/or cellular casts.

6. Patients with LN who received EC-MPS for the first time. The patients who switched
from other treatment and treatment naive patients (did not received any treatment
before) can be included in this study.

7. Women of childbearing potential must use effective contraception before beginning EC
MPS therapy, during therapy, and for six weeks after their last dose of EC MPS.

Exclusion Criteria:

1. Previous or planned kidney transplant.

2. Currently receiving continuous dialysis or GFR < 30 mL/min/1.73 m2 within 3 months
prior to the start of study.

3. Patients with active serious digestive system disease, including infrequent cases of
gastrointestinal tract ulceration with hemorrhage or perforation.

4. Patients currently with life threatening conditions including malignancies, or
severe infection in recent 6 months prior to start of study